跳至主要内容
临床试验/EUCTR2008-001974-33-NL
EUCTR2008-001974-33-NL进行中(未招募)1 期

mRNA-transfected dendritic cell vaccination in high risk uveal melanoma patients - mRNA-DC vaccination in uveal melanoma

Radboud University Nijmegen Medical Centre0 个研究点开始时间: 2008年9月25日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - histologically documented evidence of uveal melanoma
  • - HLA-A2.1 phenotype is required
  • - melanoma expressing gp100 (compulsory) and tyrosinase (non-compulsory)
  • - high risk genetic profile (loss of chromosome 3) as determined by FISH
  • - interval since local treatment of uveal melanoma is <12 months
  • - no signs of liver metastasis as determined by diagnostic CT-scan abdomen
  • - normal serum LDH
  • - WBC >3.0×109/l, lymphocytes >0.8×109/l, platelets >100×109/l,
  • serum crea-tinine <150 µmol/l, serum bilirubin <25 µmol/l
  • - no clinical signs of CNS metastases
  • - WHO performance status 0-1 (Karnofsky 100-70%)
  • - life expectancy >3 months
  • - age 18-75 years
  • - expected adequacy of follow-up
  • - no pregnant or lactating women
  • - written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - history of second malignancy, adequately treated basal cell carcinoma or carcinoma in situ of the cervix is
  • - serious active infections, HbsAg or HIV positive
  • - autoimmune diseases or organ allografts
  • - concomitant use of immunosuppressive drugs
  • - known allergy to shell fish (since it contains KLH)

研究者

发起方
Radboud University Nijmegen Medical Centre

相似试验

已完成
2 期
mRNA-transfected dendritic cell vaccination in high risk uveal melanoma patientsmelanoma of the eye10030054
NL-OMON33733niversitair Medisch Centrum Sint Radboud38
进行中(未招募)
不适用
Forsøg med dendritcellevaccination i kombination med kemoterapi til behandling af patienter med prostatakræft, der har spredt sigCastration resistent metastatic prostate cancerMedDRA version: 14.1Level: HLTClassification code 10036908Term: Prostatic neoplasms malignantSystem Organ Class: 100000004864
EUCTR2011-001602-10-DKCenter for Cancer Immunotherapy (CCIT) / Department of Oncology, Herlev Hospital
进行中(未招募)
1 期
Dendritic cell vaccine immunotherapy in paediatric high grade gliomaPaediatric High grade glioma, excluding brain stem gliomasMedDRA version: 16.1 Level: PT Classification code 10065443 Term: Malignant glioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2010-018447-34-GBGreat Ormond Street Hospital for Children NHS Trust20
已完成
不适用
Dendritic cell vaccination in patients with Lynch Syndrome or colorectal cancer with MSIhereditary non-polyposis colorectal cancerLynch syndrome100836241001799010027656
NL-OMON39056niversitair Medisch Centrum Sint Radboud25
进行中(未招募)
1 期
Dendritic cell vaccination in patients with Lynch Syndrome or colorectal cancer with MSI - DC vaccination in lynch syndrome patientsIn this study our primary objective is to induce or enhance an immune response to tumor antigens in Lynch syndrome mutation carriers (with and without colorectal adenomas or carcinomas) and patients with sporadic colorectal cancer (CRC) showing microsatellite instability (MSI-high), the hallmark of MMR dysfunction, and test the hypothesis that DC vaccination might be effective as prophylactic treatment in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) or Lynch syndrome mutation carriers.
EUCTR2008-005584-33-NLRadboud University Nijmegen Medical Centre25